Application No.	Applicant(s)
09/910.702	KONRADI ET AL.
Examiner	Art Unit
Tamthom N. Truong	1624
ears on the cover sheet with the (OR REMAINS) CLOSED in this a or other appropriate communicati GHTS. This application is subject and MPEP 1308.	correspondence address
;	
4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some* c) None of the: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient. 6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).	
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.	
6. ⊠ Interview Summar Paper No./Mail Da), 7. ⊠ Examiner's Amend	ate <u>attached</u> .
	Examiner Tamthom N. Truong ars on the cover sheet with the (OR REMAINS) CLOSED in this or other appropriate communicat GHTS. This application is subject and MPEP 1308. der 35 U.S.C. § 119(a)-(d) or (f). been received. been received in Application No. uments have been received in the first communication to file a repent of this application. det d. Note the attached EXAMINE is reason(s) why the oath or declar be submitted. on's Patent Drawing Review (PTC) Amendment / Comment or in the Mac of BIOLOGICAL MATERIAL OR THE DEPOSIT OR BIOLOGICAL OR BIOLOGICAL MATERIAL OR THE DEPOSIT OR BIOLOGICAL OR BIOLOGICAL OR BIOLOGICAL OR BIOLOG

Application/Control Number: 09/910,702

Art Unit: 1624

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Gerald Swiss on 05-06-04.

The application has been amended as follows:

Claim 28: line 5 (the definition of Ar¹), after the word 'pyrimidinyl,' delete "pyridazinyl, and pyrazinyl";

Cancel claim 30;

Claim 31: delete "or 30", and after '28,', insert – or --;

Claim 40: line 4, delete "28-39", and insert -28, 29, or 31-39— in its place.

Claim 41: line 2, delete "28-39", and insert -28, 29, or 31-39— in its place.

Remark: Claim 28 is amended to delete the non-elected subject matter. Claim 30 is cancelled as being drawn to the non-elected subject matter. Applicant has agreed to cancel non-elected subject matter without prejudice to file divisional applications. Claims 31, 40, and 41 are amended to correct the dependency.

Applicant's amendment of 02-18-04 has overcome the previous rejection of 112/1st paragraph. Thus, said rejection is withdrawn herein. With the non-elected subject matter cancelled by the above amendment, pending claims 28, 29, and 31-41 are allowed.

Art Unit: 1624

Allowable Subject Matter

The following is an examiner's statement of reasons for allowance:

The invention is drawn to compounds of pyridinone or pyrimidinone compounds of formula (Ia) or (Ib); their pharmaceutical composition, and method of treating inflammatory diseases. The closest reference, **Bisagni et. al.** (US 6,683,079 B2), teaches compounds of 3-(amino or aminoalkyl)-pyridinone. However, the disclosed compound does not have a side chain corresponding to the instant –(phenyl)-CH₂-CH-(C(=O)-X)-(N(R¹)-Ar¹). Thus, the teaching of Bisagni et. al. only shows state of the art.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Tamthom N. Truong whose telephone number is 571-272-0676. The examiner can normally be reached on M-F (~ 10 am $\sim 6:30$ pm).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mukund Shah can be reached at 571-272-0674. If you are unable to reach Dr. Shah within a 24 hour period, please contact James O. Wilson, Acting SPE of 1624, at 571-272-0661.

The fax phone numbers for the organization where this application or proceeding is assigned are 703-872-9306. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 571-272-1600.

T. Truong May 6, 2004

RICHARD L. RAYMOND PRIMARY EXAMINER